Literature DB >> 23092384

Hyperaldosteronism as a common cause of resistant hypertension.

David A Calhoun1.   

Abstract

Resistant hypertension affects an estimated 10-15 million American adults and is increasing in prevalence. The etiology of resistant hypertension is almost always multifactorial, including obesity, older age, high dietary salt, chronic kidney disease, and aldosterone excess. Classical primary aldosteronism and lesser degrees of aldosterone excess, possibly originating from visceral adipocytes, contribute broadly to antihypertensive treatment resistance. Treatment of resistant hypertension is predicated on appropriate lifestyle changes and use of effective combinations of antihypertensive agents from different classes. Blockade of aldosterone with spironolactone has been shown to be particularly effective for treatment of resistant hypertension. The antihypertensive benefit of spironolactone is not limited to patients with demonstrable hyperaldosteronism but instead can be effective in resistant hypertensive patients regardless of aldosterone levels. Chlorthalidone is a potent, long-acting thiazide-like diuretic and should be used preferentially to treat resistant hypertension as it is superior to normally used doses of hydrochlorothiazide.

Entities:  

Mesh:

Year:  2012        PMID: 23092384     DOI: 10.1146/annurev-med-042711-135929

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  22 in total

Review 1.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

2.  A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism.

Authors:  Fabio L Fernandes-Rosa; Georgios Daniil; Ian J Orozco; Corinna Göppner; Rami El Zein; Vandana Jain; Sheerazed Boulkroun; Xavier Jeunemaitre; Laurence Amar; Hervé Lefebvre; Thomas Schwarzmayr; Tim M Strom; Thomas J Jentsch; Maria-Christina Zennaro
Journal:  Nat Genet       Date:  2018-02-05       Impact factor: 38.330

Review 3.  Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retention and nocturnal rostral fluid shift.

Authors:  L H White; T D Bradley; A G Logan
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

4.  Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay.

Authors:  Ryo Morimoto; Yoshikiyo Ono; Yuta Tezuka; Masataka Kudo; Sachiko Yamamoto; Toshiaki Arai; Celso E Gomez-Sanchez; Hironobu Sasano; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Hypertension       Date:  2017-06-26       Impact factor: 10.190

Review 5.  Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.

Authors:  Robert M Carey
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

Review 6.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

Review 7.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

8.  Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.

Authors:  Lama Ghazi; Tanja Dudenbostel; Chee Paul Lin; Suzanne Oparil; David A Calhoun
Journal:  J Hypertens       Date:  2016-05       Impact factor: 4.844

9.  Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.

Authors:  Carrie C Lubitz; Konstantinos P Economopoulos; Stephen Sy; Colden Johanson; Heike E Kunzel; Martin Reincke; G Scott Gazelle; Milton C Weinstein; Thomas A Gaziano
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-11-10

Review 10.  Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.

Authors:  John E Hall; Jussara M do Carmo; Alexandre A da Silva; Zhen Wang; Michael E Hall
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.